Compare FLC & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FLC | HUMA |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | United States |
| Employees | N/A | 184 |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.0M | 155.4M |
| IPO Year | 2003 | N/A |
| Metric | FLC | HUMA |
|---|---|---|
| Price | $17.08 | $0.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $6.19 |
| AVG Volume (30 Days) | 23.3K | ★ 5.7M |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $444.16 |
| Revenue Next Year | N/A | $248.39 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.92 | $0.55 |
| 52 Week High | $18.09 | $2.93 |
| Indicator | FLC | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 50.75 | 45.53 |
| Support Level | $16.87 | $0.55 |
| Resistance Level | $17.24 | $1.27 |
| Average True Range (ATR) | 0.13 | 0.06 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 59.70 | 67.38 |
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.